NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 percent to close at 24,283.11, while the S&P 500 Index gained 0.22 percent to close at 2,723.06. The Nasdaq Composite Index jumped 0.39 percent to close at 7,561.63.
"The market is trading more on sentiment than fundamentals lately, which means moves are likely to be fickle and short lived," said Liz Young, senior investment strategist at BNY Mellon Investment Management, according to MarketWatch.
"We feel that while momentum around trade is escalating, we’re still in a place where it’s in every nation’s best interest to avoid that outcome, and that things could calm down as negotiations progress," she said. "In the meantime, the economy is still strong, data is moving in the right direction, and we don’t see this as the issue that will turn things around."
RDI Initiates Coverage on:
BioPharmX's stock moved 0.47% higher Tuesday, to close the day at $0.2367. The stock recorded a trading volume of 3,365,966 shares, which was below its three months average volume of 5,031,156 shares. In the last year, BioPharmX's shares have traded in a range of 0.10 - 0.50. The share price has gained 136.1% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.23 is above its 200-day moving average of $0.20. Shares of BioPharmX have gained roughly 4.41 percent in the past month and are up 115.45 percent year-to-date.
Access RDI's BioPharmX Corporation Research Report at:
On Tuesday, shares of DURECT recorded a trading volume of 1,343,167 shares, which was above the three months average volume of 770,128 shares. The stock ended the day 9.37% lower at $1.74. The share price has fallen 31.76% from its 52 week high with a 52 week trading range of 0.75 - 2.55. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.97 is above its 200-day moving average of $1.65. Shares of DURECT have fallen roughly 11.68 percent in the past month and are up 89.13 percent year-to-date.
Access RDI's DURECT Corporation Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.